Sleep claims

What human evidence and regulatory status actually support.

DSIP evidence is old and inconsistent, and CJC-1295/ipamorelin combinations are not validated sleep treatments.

Source-based editorial review; independent clinical review pending. Read the sources.

Evidence by peptide

• DSIP: Delta sleep-inducing peptide (DSIP) has a small, old, heterogeneous literature. The reviewed evidence does not establish a validated insomnia treatment, a reliable onset timeline, or a consumer injection protocol. [1,2]

Common Questions

• Does this page recommend a dose or stack?

  No. Trial protocols describe research, and approved-product instructions apply only to the named formulation and labeled population.

• Can animal, cell or mechanistic findings prove a human benefit?

  No. They can justify further research but cannot be rewritten as a demonstrated outcome in people.

Sources and study limits

1. Delta sleep-inducing peptide (DSIP): a still unresolved riddle Kovalzon VM, Strekalova TV. (2006)
2. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks: DSIP U.S. Food and Drug Administration
3. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks U.S. Food and Drug Administration

← Browse all peptides

Educational evidence summary. FDA approval, investigational status, and compounding are separate categories. Use the current label and a licensed clinician for patient-specific decisions.

vialprep research · Sources: PubMed, FDA, peer-reviewed trials · How we verify